Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome
Open Access
- 10 June 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 465 (7299), 813-817
- https://doi.org/10.1038/nature09106
Abstract
Down's syndrome is caused by the presence of an extra copy of chromosome 21 (a state known as trisomy), and it is known that the growth of certain tumours is reduced in this genetic disorder. A study of a mouse model of Down's syndrome points to an antitumour mechanism, the inhibition of tumour angiogenesis by the overexpression of four genes, two putative anti-angiogenic genes (ADAMTS1 and ERG) and two novel endothelial cell-specific genes not previously linked with angiogenesis (JAM-B and PTTG1IP). Down's syndrome is caused by trisomy of chromosome 21, and it is known that the growth of certain tumours is reduced in this genetic disorder. Using a mouse model of Down's syndrome, several individual genes on chromosome 21 are now being proposed to mediate the effect on tumour growth and angiogenesis. Down’s syndrome (DS) is a genetic disorder caused by full or partial trisomy of human chromosome 21 and presents with many clinical phenotypes including a reduced incidence of solid tumours1,2. Recent work with the Ts65Dn model of DS, which has orthologues of about 50% of the genes on chromosome 21 (Hsa21), has indicated that three copies of the ETS2 (ref. 3) or DS candidate region 1 (DSCR1) genes4 (a previously known suppressor of angiogenesis5,6) is sufficient to inhibit tumour growth. Here we use the Tc1 transchromosomic mouse model of DS7 to dissect the contribution of extra copies of genes on Hsa21 to tumour angiogenesis. This mouse expresses roughly 81% of Hsa21 genes but not the human DSCR1 region. We transplanted B16F0 and Lewis lung carcinoma tumour cells into Tc1 mice and showed that growth of these tumours was substantially reduced compared with wild-type littermate controls. Furthermore, tumour angiogenesis was significantly repressed in Tc1 mice. In particular, in vitro and in vivo angiogenic responses to vascular endothelial growth factor (VEGF) were inhibited. Examination of the genes on the segment of Hsa21 in Tc1 mice identified putative anti-angiogenic genes (ADAMTS18,9and ERG10) and novel endothelial cell-specific genes11, never previously shown to be involved in angiogenesis (JAM-B12 and PTTG1IP), that, when overexpressed, are responsible for inhibiting angiogenic responses to VEGF. Three copies of these genes within the stromal compartment reduced tumour angiogenesis, explaining the reduced tumour growth in DS. Furthermore, we expect that, in addition to the candidate genes that we show to be involved in the repression of angiogenesis, the Tc1 mouse model of DS will permit the identification of other endothelium-specific anti-angiogenic targets relevant to a broad spectrum of cancer patients.Keywords
This publication has 30 references indexed in Scilit:
- Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1Nature, 2009
- Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cellsNucleic Acids Research, 2004
- Down Syndrome Candidate Region 1,a Downstream Target of VEGF, Participa tes in Endothelial Cell Migration and AngiogenesisJournal of Vascular Research, 2004
- ADAMTS1/METH1 Inhibits Endothelial Cell Proliferation by Direct Binding and Sequestration of VEGF165Journal of Biological Chemistry, 2003
- ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathwayHuman Molecular Genetics, 2003
- Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based studyThe Lancet, 2002
- Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrinsNature Medicine, 2002
- Pattern of malignant disorders in individuals with Down's syndromeThe Lancet Oncology, 2001
- JAM-2, a Novel Immunoglobulin Superfamily Molecule, Expressed by Endothelial and Lymphatic CellsPublished by Elsevier BV ,2001
- A Role for Both Ets and C/EBP Transcription Factors and mRNA Stabilization in the MAPK-dependent Increase in p21Cip-1/WAF1/mda6Protein Levels in Primary HepatocytesMolecular Biology of the Cell, 2000